Worldwide blindness and prevention guidelines for front-line practitioners

Today's Therapeutic Trends

Volumn 21, Issue 1, 2003, Pages 71-83

  Phillips, Kristie A ^a   Cockrum, Paul C ^b   Kennedy, Robert H ^c  

^a U S PUBLIC HEALTH SERVICE   (United States)

^b ALCON RESEARCH LTD   (United States)

^c Exponent Health Group   (United States)

Author keywords

ARMD; Blindness; Cataract; Epidemiology; Glaucoma

Indexed keywords

ARTICLE; BLINDNESS; CATARACT; DEMOGRAPHY; DEVELOPING COUNTRY; DIABETIC RETINOPATHY; EARLY DIAGNOSIS; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; GLAUCOMA; HUMAN; INDUSTRIALIZATION; LEPROSY; MEDICAL PRACTICE; ONCHOCERCIASIS; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; PREVENTIVE MEDICINE; PUBLIC HEALTH SERVICE; RETINA MACULA AGE RELATED DEGENERATION; SCREENING TEST; TRACHOMA; XEROPHTHALMIA;

EID: 0037373683     PISSN: 07412320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Mariotti SP: A global initiative for the elimination of avoidable blindness. May 2002. Available from URL:http://www.who.int/pbd/Vision2020/V2020slides/
2. Thylefors B: A global initiative for the elimination of avoidable blindness. Am. J. Ophthalmol. 125(1):90-93, 1998.
3. Gilbert C and Foster A: Childhood blindness in the context of VISION 2020-The right to sight. Bull. World Health Organ. 79(3):227-232, 2001.
4. Thylefors B, Negrel AD, Pararajasegaram R and Dadzie KY: Global data on blindness. Bull. World Health Organ. 73:115-121, 1995.
5. Evans TG, Ranson MK, Kyaw TA and Ko CK: Cost effectiveness and cost utility of preventing trachomatous visual impairment: Lessons from 30 years of trachoma control in Burma. Br. J. Ophthalmol. 80:880-889, 1996.
6. WHO information fact sheets. Blindness and visual disability: WHO's response. February 1997 (cited 2001 March]. Available from URL: http://www.who.int/inf-fs/en/fact147.html
7. Prescott N, Prost A and LeBerre R: The economics of blindness prevention in Upper Volta under the onchocerciasis control program. Soc. Sci. Med. 19(10):1051-1055, 1984.
8. Kim A, Benton B and Tandon A: Economic assessment of the African Program for Onchocerciasis Control. World Bank, Washington, DC, 1984.
9. Tielsch JM, Sommer A, Witt K, et al., for the Baltimore Eye Study Research Group: Blindness and visual impairment in an American urban population: The Baltimore Eye Study. Arch. Ophthalmol. 108:286-290, 1990.
10. Klein R, Klein BEK, Linton KLP and DeMets DL: The Beaver Dam Eye Study: Visual acuity. Ophthalmology 98:1310-1315, 1991.
11. Kahn HA, Liebowitz HM, Ganley JP, et al.: The Framingham Eye Study monograph: Outline and major prevalence findings. Am. J. Epidemiol. 6(1):17-32, 1977.
12. Klaver CC, Wolfs RCW, Vingerling JR, et al.: Age-specific prevalence and causes of blindness and visual impairment in an older population: The Rotterdam study. Arch. Ophthalmol. 116:653-658, 1998.
13. Attebo K, Mitchell P and Smith W: Visual acuity and the causes of visual loss in Australia: The Blue Mountains Eye Study. Ophthalmology 103(3):357-364, 1996.
14. Vingerling JR, Dielemans I, Hofman A, et al.: The prevalence of age-related maculopathy in the Rotterdam study. Ophthalmology 102:205-210, 1995.
15. Klein R, Klein BEK and Linton KLP: Prevalence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology 99:933-943, 1992.
16. Sommer A, Tielsch JM, Katz J, et al.: Racial differences in the cause-specific prevalence of blindness in east Baltimore. N. Engl. J. Med. 325:1412-1417, 1991.
17. Mitchell P, Smith W, Attebo K and Wang JJ: Prevalence of age-related maculopathy in Australia: The Blue Mountains eye study. Ophthalmology 102:1450-1460, 1995.
18. World Health Organization: Use of intraocular lenses in cataract surgery in developing countries: Memorandum from a WHO meeting. Bull. World Health Organ. 69:657-666, 1991.
19. Tsukahara S, Hosada M, Asaka A, et al.: Health economics study of glaucoma treatment. Chibret Int. J. Ophthalmol. 10(3):20-28, 1994.
20. VanNewkirk MR, Weih L, McCarty CA and Taylor HR: Cause-specific prevalence of bilateral visual impairment in Victoria, Australia: The Visual Impairment Project. Ophthalmology 108(5):960-967, 2001.
21. National Society to Prevent Blindness: Vision problems in the US: Data analysis, definitions, data sources, detailed data tables, analysis, interpretation. National Society to Prevent Blindness, New York, 1980.
22. WHO Information Fact Sheets. Blindness and visual disability: Other leading causes worldwide. February 1997 Available from URL: http://www.who.int/inf-fs/en/fact144.html
23. Schwab L: Cataract blindness in developing nations. Int. Ophthalmol. Clin. 30(1):16-18, 1990.
24. World population data sheet. Population Reference Bureau, Washington, DC, 1987.
25. Whitcher JP, Srinivasan M and Upadhyay MP: Corneal blindness: A global perspective. Bull. World Health Organ. 79(3):214-221, 2001.
26. Thylefors B, Negrel AD, Pararajasegaram R and Dadzie KY: Available data on blindness (update 1994). Ophthalmic Epidemiol. 2:5-39, 1995.
27. Thylefors BA: A simplified methodology for the assessment of blindness and its main causes. World Health Statist. Quart. 40:129-141, 1987.
28. Ho VH and Schwab IR: Social economic development in the prevention of global blindness. Br. J. Ophthalmol. 85:653-657, 2001.
29. Vajpayee RB, Joshi S, Saxena R and Gupta SK: Epidemiology of cataract in India: Combating plans and strategies. Ophthalmic Res. 31:86-92, 1999.
30. WHO Information Fact Sheets. Control of major blinding diseases and disorders (2). February 2000 (cited 2001 March). Available from: URL: http://www.who.int/inf-fs/en/fact214.html
31. Kale OO: Onchocerciasis: The burden of disease. Ann. Trop. Med. Parasitol. 92:S101-S115, 1998.
32. Schaumberg DA, Linehan M, Hawley G, et al.: Vitamin A deficiency in the South Pacific. Public Health 109:311-317, 1995.
33. Noordeen SK: Elimination of leprosy as a public health problem: Progress and prospects. Bull. World Health Organ. 73(1):1-6, 1995.
34. Lewallen S, Tungpakorn NC, Kim SH and Coutright P: Progression of eye disease in "cured" leprosy patients: Implications for understanding the pathophysiology of ocular disease and for addressing eye care needs. Br. J. Ophthalmol. 84:817-821, 2000.
35. Yang J, Jian D, Hu L, et al.: Blindness and low vision in leprosy patients in Sichuan Province, China. Indian J. Lepr. 70(1):139-143, 1998.
36. Shaumberg DA and Dana MR: The epidemiology of blindness: A global overview. Practical Optometry 7:192-196, 1996.
37. AREDS Report No. 8. A randomized, placebo-controlled clinical trial of highdose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch. Ophthalmol. 19:1417-1436, 2001.
38. American Optometric Association: Recommendations for Regular Optometric Care. 2002. Available from: URL: http://www.aoanet.org/clincare/primary-care.asp
39. TM Comprehensive Adult Medical Eye Evaluation #110034, 2000.
40. TM Pediatric Eye Evaluations #110015, 1997.
41. WHO Information Fact Sheets: Global initiative for the elimination of avoidable blindness: Vision 2020. February 2000. (cited 2002 March). Available from: URL http://www.who.int/inf-fs/en/fact213.html
42. Straatsma BR, Coscas GJ, Naumann GOH, et al.: International ophthalmology strategic plan to preserve and restore vision - Vision for the future (Editorial). Am. J. Ophthalmol. 132(3):403-404, 2001.
43. Klein R, Wang Q, Klein BEK, et al.: The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest. Ophthalmol. Vis. Sci. 36(1): 182-191, 1995.